Workflow
华丽家族: 华丽家族第七届董事会第三十八次会议决议公告

Core Viewpoint - The company has approved a cash increase investment in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. with a total amount not exceeding RMB 300 million, aiming to acquire a stake of at least 5% in the company after the financing completion [1][2]. Group 1 - The board meeting was held on August 10, 2025, with all 8 directors present, and the procedures complied with relevant regulations [1]. - The company plans to subscribe for new shares at a price of RMB 4.75 per share, potentially acquiring up to 63.157895 million shares [1][2]. - After the completion of the financing, the company's stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1]. Group 2 - The company will sign a subscription agreement with Haihe Pharmaceutical and related parties, which requires approval from the shareholders' meeting [2]. - An independent director meeting was held prior to the board meeting, where the proposal was unanimously approved [2]. - The proposal will be submitted to the shareholders' meeting for further approval [2].